Low-Grade Serous Ovarian Carcinoma
Relevant Study Summaries
GOG 281: Trametinib in recurrent low-grade serous
Ovarian Cancer
MILO/ENGOT-ov11: Binimetinib in Recurrent Low-Grade Serous
In low-grade serous ovarian cancer, Binimetinib did not significantly improve PFS compared to standard of care chemotherapy.
SOC-1
Surgery did not improve overall survival, but it showed a benefit in certain analyses. This supports the potential efficacy of secondary cytoreduction in specialized centers and for selected patients.
Platinum-Resistant Recurrent Ovarian Cancer
AURELIA Trial: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer
Adding bevacizumab to chemotherapy significantly improves PFS and ORR in patients with platinum-resistant recurrent ovarian cancer.
Platinum Sensitive Recurrent Ovarian Cancer
OCEANS Trial: Bevacizumab Maintenance in Platinum Sensitive Recurrence
- Adding bevacizumab to gemcitabine and carboplatin significantly improves PFS but no difference in OS in platinum-sensitive recurrence
MITO 16B/MANGO-OV2/ENGOT-OV17: Bev Maintenance with Platinum Doublets in Platinum-sensitive Recurrence
Continuing bevacizumab beyond progression combined with chemotherapy significantly improves progression-free survival in patients with platinum-sensitive recurrent ovarian cancer compared to standard chemotherapy alone, but no OS benefit
GOG 213: Maintenance Bevacizumab in Platinum Sensitive Recurrence
The addition of bevacizumab to standard chemotherapy (paclitaxel and carboplatin) improves PFS significantly and may offer a clinically meaningful improvement in OS.
Primary Treatment of High-Grade Ovarian/Fallopian Tube Carcinoma
Primary chemotherapy treatment of ovarian cancer discussion of trials